Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary: Bacterial DNA and oligonucleotides (ODN) containing CpG‐motifs strongly activate cells of the immune system. Accordingly CpG‐DNA is a powerful adjuvant in vaccination protocols for B‐cell as well as for cytotoxic T‐cell responses. A decisive propensity of CpG‐DNA is its capacity to induce preferentially T helper type 1 (Th1)‐dominated immune responses. To exert its function CpG‐DNA has to be taken up by responsive cells, e.g. antigen‐presenting cells (APC). The rate of uptake is influenced by the DNA's backbone modification and critically determines activity of CpG‐DNA. CpG ODN with a phosphothioate backbone (PTO) are currently used for most in vivo and in vitro studies, since PTO modification protects ODN from the attack of nucleases. However, after administration of PTO‐modified CpG‐ODN long‐lasting effects including lymphadenopathy as well as sustained local interferon‐γ (IFN‐γ) and interleukin‐12 (IL‐12) production have been reported. To circumvent these restrictions we investigated the effects of DNA sequence as well as DNA backbone modification on cellular uptake and resulting immunostimulation. We show here that uptake of phosphodiester (PO)‐CpG‐ODN can be strongly enhanced by poly guanosine runs added at the 3′ end of the ODN. In addition these ODN showed an improved immunostimulatory activity in vivo and in vitro. This included protection of mice against lethal Th2‐dependent leishmaniasis as well as priming of antigen specific Th1 responses. More importantly, guanosine‐rich PO‐CpG‐ODN neither induced lymphadenopathy nor prolonged cytokine production after local administration. Since these improved PO ODN are efficient in vitro and in vivo and lack long lasting undesired effects they could be used preferably as adjuvants in vaccination protocols.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508
Cited by
Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer
Bates, P. J., Laber, D. A., Miller, D. M., Thomas, S. D., & Trent, J. O. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.004 · Cited by 874
Interferons and viruses: an evolutionary arms race of molecular interactions
Hoffmann, H.-H., Schneider, W. M., & Rice, C. M. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.01.004 · Cited by 410
The DNA Sugar Backbone 2′ Deoxyribose Determines Toll-like Receptor 9 Activation
Haas, T., Metzger, J., Schmitz, F., Heit, A., Müller, T., Latz, E., & Wagner, H. (2008) · Immunity · doi:10.1016/j.immuni.2008.01.013 · Cited by 298
Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity
Marciani, D. J. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02864-2 · Cited by 290
Marshall, J. D., Fearon, K., Abbate, C., Subramanian, S., Yee, P., Gregorio, J., Coffman, R. L., & Van Nest, G. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.1202630 · Cited by 259
Metadata
- Authors
- Dalpke, A. H., Zimmermann, S., Albrecht, I., & Heeg, K.
- Venue
- Immunology
- Publisher
- Wiley
- Published
- 2002-04-24
- Volume
- 106
- Issue
- 1
- Pages
- 102-112
- ISSN
- 0019-2805 (ISSN-L)
- 1365-2567
- OpenAlex
- W1987867113
- Cited by
- 119
- References
- 1
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. https://app.cochat.ai/papers/10.1046/j.1365-2567.2002.01410.x
- The paper
- Dalpke, A. H., Zimmermann, S., Albrecht, I., & Heeg, K. (2002). Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology. https://doi.org/10.1046/j.1365-2567.2002.01410.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.